Glenmark has cultivated inlicensing ( also outlicensing) into a strength where they target therapy and geography where they are weak and inlicense products to close the gaps…they did it in Europe with several respiratory assets followed by deals with Pfizer, beigene,cosmo etc
For me the standout point in the conall was isb 2001, being described as transformational, once in a lifetime opportunity etc…
ISB 2001 outlicen will reduce R&D spend by 60 mn USD pa apart from future payoff